stimulate greater research on authorized products and to guide academic research into the more appropriate use of medicines. However, marketed drugs, especially newly approved ones, may not necessarily have the well-established safety profile required for such trials. Guidance regarding how to define minimal risk imposed by a trial based on already available postmarketing safety data may be required. Sponsors and investigators should also ensure that the data obtained are designed to be clinically meaningful.
Other major changes introduced in the Regulation especially for clinical trials with investigational medicinal products can be grouped into four categories: first, submission of clinical trial applications (CTA); second, safety reporting during the course of a clinical trial; third, global oversight and monitoring of clinical trials; and fourth, reporting data once a trial is completed and submitting data for marketing authorization applications. We discuss these categories in more detail below (for other changes see Table 1 ).
Currently, the CTA submission procedure for multistate trials across the EU varies greatly between member states, sometimes leading to divergent assessments and at times additional bureaucratic workload.
Deciphering the EU clinical trials regulation
To the Editor: The European Union (EU; Brussels) was founded not only to unite European countries economically and politically, but also to improve collaborations among member states. Academic clinical research has been part of these collaborations, and efforts have been made to harmonize the rules governing human testing. Table 1) . We discuss here some of these provisions, their possible impact on clinical research practice in general and the biotech sector in particular, and probable barriers that may limit their full potential.
The Regulation contains the definition of the new clinical trials subcategory "low intervention clinical trials. " These are defined as trials on authorized medicinal products, used in accordance with the Summary of Product Characteristics or published evidence on their use, and where the additional procedures of the trial introduce no more than minimal risk to subject safety compared with the risk encountered in normal clinical practice. Currently, this activity is poorly regulated and is carried out by academics through the planning of comparative effectiveness trials to generate combination evidence-based medical therapies. This subcategory is expected to Reduction in the number and/or delay in the initiation of noncommercial investigator-driven trials including the ones investigating marketed medicinal products.
Clearer definition for investigator-driven trials conducted using marketed, authorized medicinal products, which will be subjected to less stringent requirements (low-intervention trials).
Several regulatory authorities are required to approve a multistate clinical trial leading to a large amount of associated paperwork and costs.
The sponsor is required to submit a single application dossier for all Concerned Member States within the EU, where the sponsor is intending to carry out a multicenter, multistate clinical trial.
Different set of forms in different EU member states are required for obtaining a clinical trial approval.
The application dossier will follow a harmonized format and will be submitted through a single web-based portal (the EU portal).
Variable approval timelines and divergent assessments of clinical trial applications are submitted by sponsors to different member states.
All member states will have to follow the specific timelines and procedures for part 1 and 2 assessment of clinical trial applications set out in the Regulation.
Reporting of all suspected serious adverse events, regardless of whether they are caused by the investigational drug or by the underlying disease, separately to all competent authorities and ethics committees.
Sponsors are required to submit their suspected unexpected serious adverse reactions (SUSARs), annual safety reports and other relevant adverse events that influence the benefit-risk balance of the trial, directly to an extended module of the EudraVigilance system.
Difficulty of obtaining a legal representative to give informed consent in clinical trials being conducted in emergency situations (e.g., sudden lifethreatening conditions).
Simplified consent requirements are provided for conducting clinical trials on vulnerable populations, including incapacitated subjects and in emergency situations.
A single sponsor is responsible for a multicenter trial, which is considered a major challenge for academic sponsors.
Multicenter clinical trials may have more than one sponsor, defined as co-sponsors, sharing the responsibilities among them.
The Regulation requires the submission of a single application dossier for all "Concerned Member States" within the EU, where the sponsor is intending to carry out a multicenter clinical trial through a single web-based portal (the EU portal). The assessment of a clinical trial application will proceed through a twofold procedure (Fig. 1) , with the 'reporting member state' coordinating the assessment of the scientific features of the trial (part 1), and each Concerned Member State carrying out a separate assessment covering national features (part 2). This coordinated assessment aims to support research in rare diseases and global epidemics, innovative therapies and personalized treatment strategies, where multicenter, multistate trials are needed to recruit enough patients 4 . Nevertheless, to achieve these objectives, the national regulatory authorities need to ensure that they have the scientific expertise and staffing to assure a timely assessment. In relation to safety reporting during the course of a clinical trial, the Regulation requires sponsors to submit their safety reports (SUSARs or suspected unexpected serious adverse reactions; and annual safety reports) directly to an extended module of the EudraVigilance system. This will replace the current national reporting system, where sponsors are required to submit safety data to competent authorities and ethics committees of the individual member states. In addition to the previously mentioned safety reports, the Regulation states that only unexpected events that influence the benefit-risk balance of the trial should be reported. However, guidance for adequately defining how a safety signal introduces a shift in the risk-benefit balance of a trial and what measures to use to easily quantify and monitor such a shift may be necessary. The perception of what affects benefit or risk may differ between regulatory agencies versus industry or academia.
The Regulation also aims to address challenges arising from the globalization of clinical research. There has been a trend toward industry conducting clinical studies outside of the EU and the United States to emerging markets 5 . Reasons may include the lower regulatory burden, less-expensive 1 and 2 ) through the EU-Portal to all concerned member states (CMSs) in which the sponsor intends to conduct the trial. The sponsor proposes one of the CMSs as the reporting member state (RMS) and an RMS is selected from among the CMSs taking account of the sponsor's proposal. The RMS is responsible for validating the application within 10 days and coordinating the assessment procedure. In case deficiencies exist, the sponsor has 10 days to respond followed by 5 days for the RMS to make a decision. The RMS then prepares a draft assessment report for part 1 of the dossier within 26 days of validation, then the report is reviewed by the CMSs within 12 days, and the RMS finalizes the report considering issues raised by the CMSs and submits it back to the CMSs and sponsor within 7 days with a conclusion (trial conduct is acceptable, acceptable subject to certain conditions, or not acceptable). If the RMS concludes that the trial is not acceptable, this shall be deemed to be the conclusion of all the CMSs, but not vice versa. The period may extend up to 31 days if the RMS requests additional information from the sponsor, plus an additional 50 days if the clinical trial involves an advanced therapy or biotech product for consultation with experts. The part 2 assessment will be conducted in parallel with the part 1 assessment and is done separately by each individual CMS within 45 days. The period may also extend up to 31 days if a CMS requests additional information from sponsor. Each CMS notifies the sponsor through the portal of its decision regarding parts 1 and 2 assessments within five days of part 1 assessment report date, or by the last day of the part 2 assessment, whichever is later. A CMS may still refuse to authorize a clinical trial and therefore participate in this trial protocol under the following circumstances: (i) where an ethics committee has issued a negative opinion which, in accordance with national law, is valid for all the CMSs; (ii) if it finds, on duly justified grounds, that the aspects of the part 2 requirements are not complied with; or (iii) if it disagrees with the RMS's conclusion in the part 1 assessment report. If any CMS fails to issue a decision within the predetermined timeframe then the conclusion of the RMS part 1 assessment report will automatically be considered as this CMS decision on the application. If parts 1 and 2 of the dossier are not submitted together, part 1 may be submitted first for assessment, followed by the part 2 up to 2 years after the part 1 assessment is completed. It should be noted that if the sponsor failed to respond to additional information requests at any stage within the predefined timelines, the application will be considered withdrawn from all CMSs. 
